Image Place holder

Janaki Parameswaran, MD


Specialty: Medical Oncology
Program: Head and Neck-Endocrine Oncology

Call 1-888-MOFFITT
(1-888-663-3488)

or call 1-888-MOFFITT
(1-888-663-3488)

Overview

Dr. Parameswaran is an Assistant Member of the Head and Neck-Endocrine Program.  She earned her medical degree from Columbia University and completed her fellowship in Hematology and Oncology at Yale University.  Her clinical and research interests are in the treatment of head and neck cancers.

Education & Training

Fellowship:

  • Yale New Haven Hospital - Hematology and Oncology

Residency:

  • Northwell Health System - Internal Medicine

Medical School:

  • Columbia University - MD
Participating Trials

CLINICAL TRIAL 17799
A Phase I Dose Escalation Trial of Stereotactic Body Radiotherapy and Concurrent Cisplatin for Re-Irradiation of Unresectable, Recurrent Squamous Cell Carcinomas of the Head and Neck
Condition: Head & Neck
Intervention: cisplatin
Open

CLINICAL TRIAL 18612
A Randomized Phase II/III Study of Adjuvant Concurrent Radiation and Chemotherapy versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors
Condition: Head & Neck
Intervention: cisplatin
Open

CLINICAL TRIAL 18906
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors
Condition: Multiple
Intervention: BMS-936558 (Nivolumab); Nivolumab; TSR-022; TSR-042
Open

CLINICAL TRIAL 18832
A Platform Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of INCB Combinations in Advanced Solid Tumors
Condition: Multiple
Intervention: Epacadostat; INCB024360 (Epacadostat); INCB039110; INCB050465
Open

CLINICAL TRIAL 18838
An Open Label, Randomized, Two Arm Phase III Study of Nivolumab in Combination with Ipilimumab versus Extreme Study Regimen (cetuximab + cisplatin/carboplatin + fluorouracil) as First Line Therapy in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Condition: Head & Neck
Intervention: 5-fluorouracil; BMS-936558 (Nivolumab); Cetuximab; Erbitux (Cetuximab); Ipilimumab; Nivolumab; Paraplatin (carboplatin); Yervoy (Ipilimumab); carboplatin; cisplatin
Open

CLINICAL TRIAL 19112
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
Condition: Multiple
Intervention: BMS-936558 (Nivolumab); Ipilimumab; Nivolumab; Yervoy (Ipilimumab)
Open

CLINICAL TRIAL 18994
Phase II Randomized Trial of Radiotherapy with or without Cisplatin for Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN) with TP53 Sequencing
Condition: Head & Neck
Intervention: Radiotherapy; cisplatin
Open

If you believe you are eligible for one of these trials or studies, please call
1-888-MOFFITT (1-888-663-3488).

Publications

  • Korsunsky I, Parameswaran J, Shapira I, Lovecchio J, Menzin A, Whyte J, Dos Santos L, Liang S, Bhuiya T, Keogh M, Khalili H, Pond C, Liew A, Shih A, Gregersen PK, Lee AT. Two microRNA signatures for malignancy and immune infiltration predict overall survival in advanced epithelial ovarian cancer. J Invest Med. 2017 Oct;65(7):1068-1076. Pubmedid: 28716985.
  • Parameswaran J, Burtness B. Immune Checkpoint Inhibition in Cancers that Affect the Head and Neck. Int J Radiat Oncol Biol Phys. 2017 Aug;98(5):969-973. Pubmedid: 28721906.